Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Lakshmi Nayak, Timothy Smith, Sarah C. Gaffey, Katherine B. Peters, Jennifer Leigh Clarke, Justin T Jordan, John Frederick De Groot, Phioanh Leia Nghiemphu, Thomas Joseph Kaley, Howard Colman, Terri Armstrong, Martin J. Taphoorn, Victoria Caruso, Myriam Bednarek Debruyne, Chinmay Bhavsar, Annette M Molinaro, Mariano Severgnini, Patrick Y. Wen, David A. Reardon
Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center, Duke Medical Center, University of California, San Francisco, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, Huntsman Cancer Institute, National Cancer Institute, Medisch Centrum Haaglanden, Stichting Haaglanden Medisch Centrum, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2892313451